Corbus Pharma Cmn (CRBP) 6.25 $CRBP
Corbus Pharmaceuticals to Present at the Jefferies Cystic Fibrosis Summit
Marketwire Canada - Mon Sep 19, 10:17AM CDT
Presentation on Thursday, September 29, 2016 at 1:15 p.m. ET
CRBP: 6.25 (-0.73)
Corbus Pharmaceuticals Announces Last Subject Enrolled in Phase 2 Study of Resunab for the Treatment of Cystic Fibrosis
Marketwire Canada - Mon Sep 12, 6:05AM CDT
Phase 2 Study to Be Completed Before Year End; Top-Line Data Expected in Early Q1 2017
CRBP: 6.25 (-0.73)
Corbus Pharmaceuticals Reports 2016 Second Quarter Financial Results and Provides Business Update
Marketwire Canada - Mon Aug 15, 6:30AM CDT
On Track to Complete Phase 2 Studies in Systemic Sclerosis and Cystic Fibrosis in Fourth Quarter of 2016
CRBP: 6.25 (-0.73)
Corbus Pharmaceuticals Announces Last Patient Enrolled in Phase 2 Study of Resunab for Systemic Sclerosis
Marketwired - Thu Jun 16, 6:01AM CDT
Top-Line Phase 2 Data on Track for 4Q 2016
CRBP: 6.25 (-0.73)
Corbus Pharmaceuticals Announces $15 Million Registered Direct Offering
Marketwired - Fri Jun 10, 8:25AM CDT
NORWOOD, MA--(Marketwired - June 10, 2016) - Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) ("Corbus" or the "Company"
, a clinical stage drug development company targeting rare, chronic, serious inflammatory and fibrotic diseases, announced today that the Company has entered into a Securities Purchase Agreement for the sale of shares of its common stock in a registered direct offering to investors, including several healthcare oriented fundamental institutional investors. The Company is selling 5,960,000 shares at a purchase price of $2.50 per share with gross proceeds to the Company totaling $14.9 million.
CRBP: 6.25 (-0.73)
Corbus Pharmaceuticals reports 1Q loss
Automated Insights - Mon May 16, 7:19AM CDT
NORWOOD, Mass. (AP) _ Corbus Pharmaceuticals Holdings Inc. (CRBP) on Monday reported a loss of $2.9 million in its first quarter.
CRBP: 6.25 (-0.73)
Corbus Pharmaceuticals Reports 2016 First Quarter Financial Results and Provides Business Update
Marketwire Canada - Mon May 16, 7:13AM CDT
Company Has Three Phase 2 Studies Ongoing With Top-Line Data Expected Starting 4Q 2016; Phase 2 Clinical Study for Treatment of Systemic Lupus Erythematosus Expected to Commence 1Q 2017
CRBP: 6.25 (-0.73)
Corbus Pharmaceuticals to Present at the 18th Annual BIO CEO & Investor Conference on February 9, 2016
Marketwired - Mon Feb 01, 6:05AM CST
Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) ("Corbus" or the "Company", a clinical stage drug development company targeting rare, chronic, and serious inflammatory and fibrotic diseases, announced today that Yuval Cohen, Ph.D., Chief Executive Officer, will present at the 18th Annual BIO CEO & Investor Conference on February 9, 2016, at 8:30 a.m. EST in New York, NY.
CRBP: 6.25 (-0.73)
Smart Money Highlights Oversold Stocks in Small Cap Biotechs
ACCESSWIRE - Tue Jan 19, 10:22AM CST
NEW YORK, NY / ACCESSWIRE / January 19, 2016 / Biotech has taken a big hit so far in 2016. At the turn of the New Year, the iShares Nasdaq Biotechnology (NASDAQ:IBB) traded at $340. At the end of last week, the index closed out at $284 - a 16% decline across a two-week period. Some companies, of course, have suffered more than others. This is especially true in the development stage as investors pull capital out of riskier small caps. Not all companies warrant their declines, however, and market weakness looks to have left a few stocks oversold. At times like these, following the smart money can help us to identify the oversolds. Here are four companies with top investor backing that could be trading at a significant discount.
VRTX: 90.63 (-1.49), CRBP: 6.25 (-0.73), RPRX: 2.16 (+0.06), IBB: 298.18 (-1.90), AKBA: 9.14 (-0.11), EPZM: 9.70 (-0.04)
Corbus Pharmaceuticals to Present at Biotech Showcase(TM) on January 12, 2016
Marketwired - Tue Jan 05, 6:05AM CST
Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) ("Corbus" or the "Company", a clinical stage drug development company targeting rare, chronic, and serious inflammatory and fibrotic diseases, announced today that Yuval Cohen, Ph.D., Chief Executive Officer, will present at the 8th Annual Biotech Showcase(TM) conference on Tuesday, January 12, 2016 at 11:00 a.m. PT in San Francisco, CA.
CRBP: 6.25 (-0.73)
Corbus Pharmaceuticals to Present at Two Upcoming Investor Conferences in December 2015
Marketwired - Mon Nov 23, 6:05AM CST
Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) ("Corbus" or the "Company", a clinical stage drug development company targeting rare, chronic, and serious inflammatory and fibrotic diseases, announced today that Yuval Cohen, Ph.D., Chief Executive Officer, will present at two upcoming investor conferences in December.
CRBP: 6.25 (-0.73)
Corbus Pharmaceuticals Reports 2015 Third Quarter Financial Results
Marketwired - Wed Nov 11, 6:05AM CST
Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) ("Corbus" or the "Company", a clinical stage drug development company targeting rare, chronic, and serious inflammatory and fibrotic diseases, announced today its financial results for the quarter ended September 30, 2015.
CRBP: 6.25 (-0.73)
Cystic Fibrosis Conference Opens up New Treatment Possibilities
ACCESSWIRE - Mon Oct 26, 8:50AM CDT
NEW YORK, NY / ACCESSWIRE / October 26, 2015 / Earlier this month, the Annual North American Cystic Fibrosis Conference (NACFC) took place in Arizona. Among the companies that presented were a range of public pharmas that, combined, cover the full spectrum of in-development cystic fibrosis therapies. CF is a rare disease but a big money maker, as some of the most expensive drugs in the world are CF drugs. Here's a look at each company, with a discussion on their respective approaches.
CRBP: 6.25 (-0.73)
Corbus Pharmaceuticals Holdings wins US FDA Fast Track development programme status & orphan drug designation for Resunab for cystic fibrosis
M2 - Wed Oct 21, 3:06AM CDT
Drug development company Corbus Pharmaceuticals Holdings (NASDAQ:CRBP) disclosed on Tuesday the receipt of the US Food and Drug Administration's (FDA) Fast Track development programme status plus orphan drug designation for its investigational new drug Resunab for the treatment of cystic fibrosis (CF).
CRBP: 6.25 (-0.73)
Corbus Pharmaceuticals Announces FDA Orphan Drug Designation and Fast Track Status of Resunab(TM) for the Treatment of Cystic Fibrosis
Marketwired - Tue Oct 20, 7:05AM CDT
Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) ("Corbus" or the "Company", a clinical stage drug development company targeting rare, chronic, and serious inflammatory and fibrotic diseases, announced today that the U.S. Food and Drug Administration ("FDA" has designated as a Fast Track development program and granted Orphan Drug Designation to the Company's investigational new drug Resunab(TM) for the treatment of cystic fibrosis ("CF".
CRBP: 6.25 (-0.73)
Corbus Pharmaceuticals Holdings treats fisrt subject with Resunab for cystic fibrosis
M2 - Fri Oct 16, 3:10AM CDT
Drug company Corbus Pharmaceuticals Holdings (NASDAQ:CRBP) said on Thursday that its first subject has been dosed with its investigational new drug Resunab. for the treatment of cystic fibrosis (CF) under its Phase 2 clinical study, with expected top-line data at end of 2016.
CRBP: 6.25 (-0.73)
Corbus Pharmaceuticals to Present at the Jefferies Cystic Fibrosis Summit
Marketwire Canada - Mon Sep 19, 10:17AM CDT
Presentation on Thursday, September 29, 2016 at 1:15 p.m. ET
CRBP: 6.25 (-0.73)
Corbus Pharmaceuticals Announces Last Subject Enrolled in Phase 2 Study of Resunab for the Treatment of Cystic Fibrosis
Marketwire Canada - Mon Sep 12, 6:05AM CDT
Phase 2 Study to Be Completed Before Year End; Top-Line Data Expected in Early Q1 2017
CRBP: 6.25 (-0.73)
Corbus Pharmaceuticals Reports 2016 Second Quarter Financial Results and Provides Business Update
Marketwire Canada - Mon Aug 15, 6:30AM CDT
On Track to Complete Phase 2 Studies in Systemic Sclerosis and Cystic Fibrosis in Fourth Quarter of 2016
CRBP: 6.25 (-0.73)
Corbus Pharmaceuticals Announces Last Patient Enrolled in Phase 2 Study of Resunab for Systemic Sclerosis
Marketwired - Thu Jun 16, 6:01AM CDT
Top-Line Phase 2 Data on Track for 4Q 2016
CRBP: 6.25 (-0.73)
Corbus Pharmaceuticals Announces $15 Million Registered Direct Offering
Marketwired - Fri Jun 10, 8:25AM CDT
NORWOOD, MA--(Marketwired - June 10, 2016) - Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) ("Corbus" or the "Company"
, a clinical stage drug development company targeting rare, chronic, serious inflammatory and fibrotic diseases, announced today that the Company has entered into a Securities Purchase Agreement for the sale of shares of its common stock in a registered direct offering to investors, including several healthcare oriented fundamental institutional investors. The Company is selling 5,960,000 shares at a purchase price of $2.50 per share with gross proceeds to the Company totaling $14.9 million. CRBP: 6.25 (-0.73)
Corbus Pharmaceuticals reports 1Q loss
Automated Insights - Mon May 16, 7:19AM CDT
NORWOOD, Mass. (AP) _ Corbus Pharmaceuticals Holdings Inc. (CRBP) on Monday reported a loss of $2.9 million in its first quarter.
CRBP: 6.25 (-0.73)
Corbus Pharmaceuticals Reports 2016 First Quarter Financial Results and Provides Business Update
Marketwire Canada - Mon May 16, 7:13AM CDT
Company Has Three Phase 2 Studies Ongoing With Top-Line Data Expected Starting 4Q 2016; Phase 2 Clinical Study for Treatment of Systemic Lupus Erythematosus Expected to Commence 1Q 2017
CRBP: 6.25 (-0.73)
Corbus Pharmaceuticals to Present at the 18th Annual BIO CEO & Investor Conference on February 9, 2016
Marketwired - Mon Feb 01, 6:05AM CST
Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) ("Corbus" or the "Company"
, a clinical stage drug development company targeting rare, chronic, and serious inflammatory and fibrotic diseases, announced today that Yuval Cohen, Ph.D., Chief Executive Officer, will present at the 18th Annual BIO CEO & Investor Conference on February 9, 2016, at 8:30 a.m. EST in New York, NY. CRBP: 6.25 (-0.73)
Smart Money Highlights Oversold Stocks in Small Cap Biotechs
ACCESSWIRE - Tue Jan 19, 10:22AM CST
NEW YORK, NY / ACCESSWIRE / January 19, 2016 / Biotech has taken a big hit so far in 2016. At the turn of the New Year, the iShares Nasdaq Biotechnology (NASDAQ:IBB) traded at $340. At the end of last week, the index closed out at $284 - a 16% decline across a two-week period. Some companies, of course, have suffered more than others. This is especially true in the development stage as investors pull capital out of riskier small caps. Not all companies warrant their declines, however, and market weakness looks to have left a few stocks oversold. At times like these, following the smart money can help us to identify the oversolds. Here are four companies with top investor backing that could be trading at a significant discount.
VRTX: 90.63 (-1.49), CRBP: 6.25 (-0.73), RPRX: 2.16 (+0.06), IBB: 298.18 (-1.90), AKBA: 9.14 (-0.11), EPZM: 9.70 (-0.04)
Corbus Pharmaceuticals to Present at Biotech Showcase(TM) on January 12, 2016
Marketwired - Tue Jan 05, 6:05AM CST
Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) ("Corbus" or the "Company"
, a clinical stage drug development company targeting rare, chronic, and serious inflammatory and fibrotic diseases, announced today that Yuval Cohen, Ph.D., Chief Executive Officer, will present at the 8th Annual Biotech Showcase(TM) conference on Tuesday, January 12, 2016 at 11:00 a.m. PT in San Francisco, CA. CRBP: 6.25 (-0.73)
Corbus Pharmaceuticals to Present at Two Upcoming Investor Conferences in December 2015
Marketwired - Mon Nov 23, 6:05AM CST
Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) ("Corbus" or the "Company"
, a clinical stage drug development company targeting rare, chronic, and serious inflammatory and fibrotic diseases, announced today that Yuval Cohen, Ph.D., Chief Executive Officer, will present at two upcoming investor conferences in December. CRBP: 6.25 (-0.73)
Corbus Pharmaceuticals Reports 2015 Third Quarter Financial Results
Marketwired - Wed Nov 11, 6:05AM CST
Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) ("Corbus" or the "Company"
, a clinical stage drug development company targeting rare, chronic, and serious inflammatory and fibrotic diseases, announced today its financial results for the quarter ended September 30, 2015. CRBP: 6.25 (-0.73)
Cystic Fibrosis Conference Opens up New Treatment Possibilities
ACCESSWIRE - Mon Oct 26, 8:50AM CDT
NEW YORK, NY / ACCESSWIRE / October 26, 2015 / Earlier this month, the Annual North American Cystic Fibrosis Conference (NACFC) took place in Arizona. Among the companies that presented were a range of public pharmas that, combined, cover the full spectrum of in-development cystic fibrosis therapies. CF is a rare disease but a big money maker, as some of the most expensive drugs in the world are CF drugs. Here's a look at each company, with a discussion on their respective approaches.
CRBP: 6.25 (-0.73)
Corbus Pharmaceuticals Holdings wins US FDA Fast Track development programme status & orphan drug designation for Resunab for cystic fibrosis
M2 - Wed Oct 21, 3:06AM CDT
Drug development company Corbus Pharmaceuticals Holdings (NASDAQ:CRBP) disclosed on Tuesday the receipt of the US Food and Drug Administration's (FDA) Fast Track development programme status plus orphan drug designation for its investigational new drug Resunab for the treatment of cystic fibrosis (CF).
CRBP: 6.25 (-0.73)
Corbus Pharmaceuticals Announces FDA Orphan Drug Designation and Fast Track Status of Resunab(TM) for the Treatment of Cystic Fibrosis
Marketwired - Tue Oct 20, 7:05AM CDT
Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) ("Corbus" or the "Company"
, a clinical stage drug development company targeting rare, chronic, and serious inflammatory and fibrotic diseases, announced today that the U.S. Food and Drug Administration ("FDA" has designated as a Fast Track development program and granted Orphan Drug Designation to the Company's investigational new drug Resunab(TM) for the treatment of cystic fibrosis ("CF". CRBP: 6.25 (-0.73)
Corbus Pharmaceuticals Holdings treats fisrt subject with Resunab for cystic fibrosis
M2 - Fri Oct 16, 3:10AM CDT
Drug company Corbus Pharmaceuticals Holdings (NASDAQ:CRBP) said on Thursday that its first subject has been dosed with its investigational new drug Resunab. for the treatment of cystic fibrosis (CF) under its Phase 2 clinical study, with expected top-line data at end of 2016.
CRBP: 6.25 (-0.73)
